GlassScriptPhysician profile
Gabriel Delgado
NPI 1770128845
$1,193.23
in general payments reported to CMS, 2019-2025
28 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $403 · 2022: $97.59 · 2023: $510 · 2024: $30.47 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $166.44 | 2021 | |
| Atricure, INC. | $139.14 | 2023 | |
| Janssen Biotech, INC. | $114.68 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $88.22 | 2022-2025 | Keytruda |
| Collegium Pharmaceutical, INC. | $64.16 | 2021 | |
| Scilex Pharmaceuticals INC. | $53.98 | 2021 | |
| Incyte Corporation | $53.04 | 2025 | Monjuvi, Zynyz |
| Nalu Medical, INC. | $43.28 | 2021 | |
| Kyowa Kirin, INC. | $37.46 | 2023 | Poteligeo |
| Pfizer INC. | $37.45 | 2023 | |
| Emd Serono, INC. | $36.31 | 2023 | Bavencio |
| Jazz Pharmaceuticals INC. | $35.42 | 2023 | |
| Amgen INC. | $35.21 | 2022 | |
| Coherus Oncology, INC. | $30.47 | 2024 | |
| Seagen INC. | $26.53 | 2023 | Padcev |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $23.25 | 2023 | Polivy |
| Arbor Pharmaceuticals, INC. | $20.56 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.08 | 2022 | |
| G1 Therapeutics, INC. | $19.23 | 2023 | Cosela |
| Biohaven Pharmaceuticals, INC. | $18.88 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.79 | 2023 | Tazverik |
| Biodelivery Sciences International, INC. | $18.45 | 2021 | |
| Nevro Corp. | $17.65 | 2021 | |
| Apellis Pharmaceuticals, INC. | $17.46 | 2023 | Empaveli |
| Glaxosmithkline, LLC. | $16.30 | 2023 | Zejula, Jemperli |
| Tersera Therapeutics LLC | $15.94 | 2023 | Zoladex |
| Celgene Corporation | $12.77 | 2022 | |
| Lilly USA, LLC | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Delgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.